Express Scripts 2013 Annual Report Download - page 99

Download and view the complete annual report

Please find page 99 of the 2013 Express Scripts annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 124

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124

99 Express Scripts 2013 Annual Report
The following table presents the balance sheet information about our reportable segments, including the
discontinued operations of our acute infusion therapies line of business, the businesses within UBC that were sold, EAV and
our European operations:
(in millions) PBM
Other
Business
Operations
Discontinued
Operations Total
As of December 31, 2013
Total assets $ 52,599.1 $ 918.1 $ 31.0 $ 53,548.2
Investment in equity method investees $ 30.2 $ — $ — $ 30.2
As of December 31, 2012
Total assets $ 54,510.8 $ 3,021.2 $ 579.2 $ 58,111.2
Investment in equity method investees $ 11.9 $ — $ — $ 11.9
PBM product revenues consist of revenues from the sale of prescription drugs by retail pharmacies in our retail
pharmacy networks, revenues from the dispensing of prescription drugs from our home delivery pharmacies and revenues from
the sale of certain fertility and specialty drugs. Other Business Operations product revenues consist of specialty distribution
activities and development of scientific evidence to guide the safe, effective and affordable use of medicines. PBM service
revenues include administrative fees associated with the administration of retail pharmacy networks contracted by certain
clients, informed decision counseling services and specialty pharmacy services. Other Business Operations service revenues
include revenues related to data analytics and research associated with our UBC business as well as from healthcare card
administration through September 14, 2012, the date of disposal of CYC.
The following table shows the percentage of total revenue represented by our top five clients and clients
representing 10% or greater of our consolidated revenue for each respective period:
December 31,
2013 2012 2011
WellPoint 12.2% 13.7% 29.5%
Department of Defense (“DoD”) 10.2% 10.6% 20.9%
Other 16.0% 15.0% 6.3%
Top five clients 38.4% 39.3% 56.7%
None of our other clients accounted for 10% or more of our consolidated revenues during the years ended
December 31, 2013, 2012 or 2011.
Revenues earned by our continuing operations international businesses totaled $98.6 million, $77.1 million and
$62.4 million for the years ended December 31, 2013, 2012 and 2011, respectively. All other continuing operations revenues
were earned in the United States. Long-lived assets of our continuing operations international businesses (consisting primarily
of fixed assets) totaled $58.6 million and $32.6 million as of December 31, 2013 and 2012, respectively. All other continuing
operations long-lived assets are domiciled in the United States.